Cost-effectiveness of fluoxetine plus pindolol in patients with major depressive disorder: results from a randomized, double-blind clinical trial

This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. The results show that fluoxetine plus pindolol, over a course of 6 weeks of treatment, incurs lower direct medical costs than treatment with fluoxetine plus placebo, whilst increasing therapeutic response, increasing remission and reducing admission to hospital.